Introduction
============

Lung cancer is the main type of tumor associated with mortality worldwide and is becoming increasingly more prevalent worldwide ([@b1-or-41-04-2226]). Lung cancer is a severe disease that poses a threat to the health of the Chinese population. It includes small cell lung cancer and non-small cell lung cancer (NSCLC); NSCLC represents \~85% of lung cancer ([@b2-or-41-04-2226]). Furthermore, a large percentage of the patient population has a very late stage of the disease when they are first diagnosed with lung cancer, which increases the difficulty of treating this disease ([@b3-or-41-04-2226]--[@b7-or-41-04-2226]). Many chemotherapy drugs and targeted medicines have been applied in the clinic, including Bevacizumab, Pemetrexed, Gemcitabine and Platinum ([@b8-or-41-04-2226]). EGFR mutations are easily identified in female patients who do not smoke, and the anaplastic lymphoma kinase receptor tyrosine kinase (ALK) fusion gene is also common in patients with lung cancer ([@b9-or-41-04-2226]--[@b12-or-41-04-2226]). Fortunately, there are targeted medicines for these patients, including Gefitinib, Erlotinib and Icotinib for patients with the EGFR mutation, and Crizotinib for patients with the ALK fusion gene. According to a report including 741 patients with Chinese lung adenocarcinoma, patients with EGFR mutation account for \~50.2% of the population ([@b13-or-41-04-2226]). Another report revealed that the patients with ALK gene rearrangements account for \~8.1% of Chinese NSCLC patients, the majority of whom are younger patients ([@b14-or-41-04-2226]). Therefore, gene testing is required for lung cancer patients and may also support future treatment. The search for novel targets of cancerous diseases is also imperative for developing new disease therapeutics.

MicroRNA (miRNA/miR) is a class of non-coding single- stranded RNA with a length of 22 nucleotides. miRNA has multiple target genes that regulate the downstream pathways. Once miRNA combines with target mRNA, the expression of mRNA is downregulated as miRNA inhibits protein translation or mRNA is degraded directly. Previous studies have shown that miRNAs have abnormal levels in many cancerous diseases ([@b15-or-41-04-2226]--[@b19-or-41-04-2226]). Our previous study concluded that low expression of miR-146a in NSCLC cells inhibited cell proliferation and metastasis, and induced apoptosis through the epidermal growth factor receptor (EGFR) signaling pathway ([@b20-or-41-04-2226]). Thus, miRNA serves an important role in tumor biological function through targeting downstream mRNAs and regulating their expression.

Currently, many high-throughput experimental studies and array analyses are based on the mechanism of miRNA binding to hundreds of mRNAs. Various mechanisms involving the recruitment of the miRNA-induced silencing complex (miRISC) have been associated with specific mRNA targets and a reduction in the levels of target proteins ([@b21-or-41-04-2226],[@b22-or-41-04-2226]). At the 5′ end of miRNA, a 6--8 nucleotide region interacts with target mRNA sites. These sites are closely associated with the miRNA-dependent degradation of mRNA. These sites can be the primary focus of miRNA target gene prediction databases *in silico*, such as TargetScan ([@b23-or-41-04-2226]) or miRbase ([@b24-or-41-04-2226]). When the expression level of miRNA is altered, the majority of the predicted targeted genes either undergo some changes at the RNA or protein levels, or exert phenotypic consequences through biogenesis pathways.

Tumor collagenase stimulatory factor (TCSF) is a type of transmembrane glycoprotein that is a part of the immunoglobulin superfamily. It is also known as Basigin, cluster of differentiation 147 (CD147), HAB18G or extracellular matrix metalloproteinase inducer. TCSF is closely associated with monocarboxylate transporters (MCTs) and supports their cell surface translocation and activities ([@b25-or-41-04-2226]). As a chaperone for some MCT isoforms, TCSF also serves important roles in cancer pathogenesis and its upregulated expression level functions in tumor metabolic transformation. With the acceleration of lactate efflux and aerobic glycolysis, TCSF provides the cancerous cells with an acidic microenvironment that makes the cells metabolic and invasive ([@b26-or-41-04-2226]). TCSF takes part in various biological processes, including growth, invasion, glycolysis and metastasis of malignant cells. Additionally, angiogenesis, anoikis resistance and multidrug resistance are also associated with the function of TCSF ([@b27-or-41-04-2226]). Cell viability, proliferation and apoptosis can be induced by TCSF-mediation of vascular endothelial growth factor (VEGF), whereas stimulation of tumor cell invasion is associated with TCSF-induced matrix metalloproteinases (MMPs). Therefore, TCSF has the potential to be a novel target of cancer therapy. As reported recently, TCSF silencing could suppress the progression of malignant melanoma ([@b28-or-41-04-2226]).

In the present study, the sequences of miR-146a-5p and TCSF were determined using bioinformatics prediction and their complementary relationships were verified by a dual-luciferase reporter system. The expression levels of miR-146a-5p and TCSF also demonstrated their reverse regulation mechanism. Furthermore, an *in vitro* experiment revealed that miR-146a-5p had a role in cell viability, proliferation and apoptosis by regulating the target gene TCSF.

Materials and methods
=====================

### Targeted gene prediction

The microRNA database miRanda, ([www.microrna.org/](www.microrna.org/)), the miRDB database ([www.mirdb.org/](www.mirdb.org/)), the TargetScanHuman release 7.1 database ([www.targetscan.org/vert_71/](www.targetscan.org/vert_71/)) and miRwalk 2.0 ([zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk/micrornapredictedtarget.html](zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk/micrornapredictedtarget.html)) ([@b29-or-41-04-2226]--[@b33-or-41-04-2226]) were used to predict the miRNAs and were searched using the targeted gene symbol. These databases can list the targeted mRNAs of miRNAs and show the binding sites with different algorithms.

In order to investigate the function of potential target genes, Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation were summarized using the Database for Annotation, Visualization, and Integrated Discovery online tool (DAVID; version 6.8; [david.ncifcrf.gov/home.jsp](david.ncifcrf.gov/home.jsp)). The 10 most significant GO terms following enrichment analysis and 10 KEGG pathways (all P\<0.05) were chosen for subsequent analysis. The software Cytoscape 3.5.1 ([cytoscape.org](cytoscape.org)) was used analyze the results of the enrichment analysis of biological process (BP), cellular component (CC) and molecular function (MF).

### Expression of miR-146a-5p and TCSF from The Cancer Genome Atlas (TCGA)

TCGA ([cancergenome.nih.gov/](cancergenome.nih.gov/)) program was started in 2006 and is a collaboration of the National Cancer Institute and the National Human Genome Research Institute. It contains information on key genomic changes in 33 types of cancers. In the present study, the 'Transcriptome Profiling' and 'miRNA' files for lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) were downloaded from TCGA ([@b32-or-41-04-2226],[@b34-or-41-04-2226]--[@b37-or-41-04-2226]). Then, the miRNA and mRNA expression levels of miR-146a-5p and TCSF were extracted and standardized. The expression of mature miR-146a-5p in TCGA from University of California Santa Cruz Xena ([xena.ucsc.edu/](xena.ucsc.edu/)) was also downloaded. Two datasets, TCGA LUAD miRNA mature strand expression by RNAseq (IlluminaHiseq, n=495) and TCGA LUSC miRNA mature strand expression by RNAseq (IlluminaHiseq; n=380), were obtained from UCSC Xena. In addition, the expression profiling by arrays were searched within Gene Expression Omnibus (GEO) DataSets ([www.ncbi.nlm.nih.gov/gds/](www.ncbi.nlm.nih.gov/gds/)).

### Detection of TCSF protein expression in clinical tissues by immunohistochemistry

The present study obtained 371 lung cancer patient tissues (age, 53.58±10.9 years) and 30 non-cancerous tissues (age, 54.03±12.2 years) from the Pathology Department, First Affiliated Hospital of Guangxi Medical University (Guangxi, China) (n=395; male/female ratio, 3.1:1). The tissues were collected between January 2010 and February 2014; the inclusion criteria included any tissues that contained adenocarcinoma, squamous carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, large cell carcinoma or small cell carcinoma. The experiments were approved by the Ethical Committee of the First Affiliated Hospital of Guangxi Medical University and written informed consent was signed by each participant. Hematoxylin and eosin staining was applied to observe the pathological histology of lung cancer tissues. Briefly, lung tissues were immersed in 4% paraformaldehyde for 4 h at room temperature and transferred to 70% ethanol. Individual lung tissue biopsy material was placed in processing cassettes, dehydrated through a serial alcohol gradient and embedded in paraffin wax blocks. Prior to staining, lung tissues were sliced into 5 µm thick, then dewaxed in xylene, rehydrated through decreasing concentrations of ethanol (from absolute ethyl alcohol to 75% ethanol) and washed in distilled water. The sections were stained with hematoxylin for 10 min and eosin for 2 min at room temperature, and then dehydrated through increasing concentrations of ethanol and xylene.

In the present study, TCSF protein expression was detected by immunohistochemistry (IHC) with the anti-CD147 (TCSF) antibody (cat. no. EPR4052; 1:250 dilution; Abcam, Cambridge, MA, USA). SPlink Detection kits (Biotin-Streptavidin HRP Detection Systems; cat. no. SP-9000; ZSGB-BIO; OriGene Technologies, Inc., Beijing, China) was used in the IHC experiments. Sections were blocked with 10% goat serum (included in the SPlink Detection kit) for 20 min at room temperature. Then the primary antibody was added and incubated for 1 h at room temperature. Then, 100 µl of the secondary antibody (Goat Anti-Rabbit Immunoglobulin G; included in the aforementioned SPlink Detection kit) was added for incubation for 15 min at room temperature, according to the kit instructions. Five random images were captured with a light microscope. The percentage of positive TCSF staining was scored by 0--4, which indicated 0 to ≤10, \>10 to ≤25, 25 to ≤50, 50 to ≤75 and 75 to ≤100%, respectively. The weak, moderate and strong intensities of TCSF staining were scored using 1, 2 and 3, respectively. The scoring criteria were examined by two independent pathologists. When the score was \>2, positive TCSF staining was confirmed and otherwise the sample was considered negative ([@b38-or-41-04-2226],[@b39-or-41-04-2226]).

### Cell culture

The human lung adenocarcinoma cell line A549 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The A549 cell line was cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, Logan, UT, USA) and 100 U/ml penicillin-streptomycin sulfate in the 5% carbon dioxide (CO~2~) at a temperature of 37°C. When the confluence of cells reached 80--90%, the cells were passaged and frozen at −80°C. Cell media was changed every 3 days.

### Vector construction and luciferase reporter assay

The A549 lung cancer cell line was cultured with RPMI-1640 and 10% FBS during these experiments. A luciferase reporter assay kit was purchased from Promega Corporation (Madison, WI, USA). The pGL3 reporter vector was applied to construct the TCSF wild type (TCSF-wt) plasmid and TCSF mutant type (TCSF-mut) plasmid. The miR-146a mimic and miRNA mimic negative control (NC) were synthesized by Ambion (Thermo Fisher Scientific, Inc.). When the cells reached high confluency (\>80%), culture medium without FBS or penicillin-streptomycin was placed into 48-well plates. The recombined plasmids and miR-146a mimics/NC were transfected with Lipofectamine 2000™ (Thermo Fisher Scientific, Inc.) into the prepared cells (\~1×10^5^/well). Following 6 h of transfection, the cells were cultured with new culture medium supplemented with 10% FBS for 24 h. A GloMax™ 96 Microplate Luminometer was then used to detect the fluorescence intensity values. Firefly luciferase activity and *Renilla* luciferase activity were detected and the results were normalized to those of *Renilla* luciferase.

### Small interfering (si)-RNA transfection

The primer sequences of the siRNA (synthesized by Ruibiotech, Inc., Beijing, China) used were as follows: TCSF sense, 5′-GGUCAGAGCUACACAUUGA-3′ and antisense, 5′-UCAAUGUGUAG-CUCUGA CC-3′; NC siRNA (the scrambled siRNA control group), sense, 5′-UUCUCCGAACGUGUCACGU-3′ and antisense, 5′-ACGUGACACGUUCGGAGAA-3′. The TCSF and NC siRNAs were transfected with Lipofectamine 2000™ (Thermo Fisher Scientific, Inc.) using 2.5 µg siRNA (20 µM is \~0.26 µg/µl; diluted to 9.62 µl/well of a 6-well plate). Following 6 h of the transfection, the cells were cultured with new culture medium supplemented with 10% FBS at 37°C for 48 h.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from cells using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. cDNA synthesis and RT-qPCR reactions were performed in the LightCycler 1.5 instrument, initially with SYBR-Green detection. The LightCycler FastStart DNA MasterPLUS SYBR-Green kit (Roche Diagnostics, Basel, Switzerland) was used. The thermocycling conditions were as follows: 10 min at 95°C, followed by denaturation at 95°C for 10 sec, annealing at 60°C for 5 sec and extension at 72°C for 5 sec. The primer sequences were as follows: TCSF, sense 5′-CCATGCTGGTCTGCAAGTCAG-3′ and antisense 5′-CCGTTCATGAGGGCCTTGTC-3′; and GAPDH, sense 5′-CTATAAATTGAGCCCGCAGC-3′ and antisense 5′-GACCAAATCCGTTGACTCCG-3′. The original Cq value of GAPDH and TCSF was exported directly from the instrument and the experiment was repeated 3 times. RT-qPCR analyses for TCSF and the normalization control gene GAPDH were performed using the 2^−∆∆Cq^ method ([@b40-or-41-04-2226]). When the expression of TCSF in the TCSF siRNA group was significantly decreased compared to the scrambled siRNA control group (P\<0.05), the cell viability, proliferation and apoptosis assays proceeded.

### Cell viability assay

The CellTiter-Blue Cell Viability Assay kit (cat. no. G8080; Promega Corporation) was used to perform the cell viability assay. A549 cells were cultured and prepared in a 96-well plate (3×10^4^/well). First, the frozen cells were added to 20 ml CellTiter-Blue Reagent and incubated at room temperature for 90 min. Then, the solution was added to a 96-well plate with 20 µl/well and the plate was shaken for 10 sec. The cells in the 96-well plate were cultured in 5% CO~2~ at 37°C for 2 h. Then, the plate was shaken for 10 sec. The absorbance fluorescence values were measured at 560/590 nm ([@b41-or-41-04-2226]--[@b44-or-41-04-2226]).

### Cell proliferation assay

A Promega MTS kit (cat. no. G3580; Promega Corporation) was applied for the cell proliferation assay. A549 cells were cultured and prepared in a 96-well plate for use (3×10^4^/well). First, thawed CellTiter 96 AQueous One Solution Reagent and cells were incubated at room temperature for 90 min. The mixture was then added to a 96-well plate with 20 µl/well and the plate was shaken for 10 sec. The cells in the 96-well plate were cultured in 5% CO~2~ at 37°C for 2 h. Then, the plate was shaken for 10 sec. The absorbance fluorescence values were measured at 490 nm ([@b42-or-41-04-2226],[@b43-or-41-04-2226],[@b45-or-41-04-2226]--[@b48-or-41-04-2226]).

### Cell apoptosis analysis

The cell apoptosis analysis experiment was conducted via an Apo-ONE Homogeneous Caspase-3/7 Assay (cat. no. G7790; Promega Corporation). A549 cells were cultured and prepared in a 96-well plate for use. The Caspase Substrate and Apo-ONE Caspase-3/7 Buffer were thawed and mixed to produce the Apo-ONE Caspase-3/7 Reagent, then mixed reagent was added to a 96-well plate containing blanks (only cells), controls (cells transfected with scrambled siRNA) and samples (cells transfected with TCSF siRNA or TCSF siRNA + miR-146a-5p inhibitor/mimic). All of the mixed contents were incubated for 1 h at room temperature. Under a 499-nm excitation wavelength for detection and 521-nm emission maximum, the absorbance fluorescence values were measured ([@b41-or-41-04-2226],[@b42-or-41-04-2226],[@b44-or-41-04-2226],[@b49-or-41-04-2226]).

Hoechst 33342 and propidium iodide (PI; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were also used to stain cells to determine the level of cell apoptosis. Cells were stained with a mixture of 5 µl Hoechst 33342 and 5 µl PI at 4°C for 20 min. The stained cells were observed under a fluorescent microscope with a magnification of ×200. The cell membrane can be penetrated by Hoechst 33342 and then combined with double-stranded DNA to emit blue fluorescence. However, PI does not penetrate the membrane of viable cells, but instead stains the nucleus of apoptotic cells red. Normal cells show weak intensity of red and blue fluorescence. Apoptotic cells exhibit weak red fluorescence but strong blue fluorescence. Necrotic cells present a strong intensity of red and blue fluorescence ([@b41-or-41-04-2226],[@b44-or-41-04-2226]).

### Statistical analysis

Statistical analysis was performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA). GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) was applied to plot the results. A pairwise comparison using a method of a Student\'s t-test and a non-parametric test or one-way analysis variance (ANOVA) with a Bonferroni post hoc test was used for comparisons among groups. Qualitative data were analyzed by Pearson\'s chi-squared test. When there were ≥3 comparison objects, the χ^2^ method (Student-Newman-Keuls and Newman-Keuls tests) was used. For correlation analysis in GraphPad Prism 7.0, the expression of mir-146a and TCSF from the TCGA database was listed in two columns. 'Analyze' was selected to start the correlation analysis and 'assume data are sampled from Gaussian populations (Pearson)' was chosen. Then Pearson r and P-values were produced. The results of cell viability, proliferation and apoptosis analysis were analyzed using Variance Analysis of Randomized Block Design ANOVA and Bonferroni multiple comparisons post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

The statistical analysis of miR-146a-5p expression from different databases was performed using Stata Statistical software version 12.0 (StataCorp LP, College Station, TX, USA). Standard mean difference (SMD) with 95% confidence interval (CI) was evaluated for the continuous outcomes. If heterogeneity existed (P\<0.05 or I2\>50%), the SMDs were pooled by random-effect models (DerSimonian-Laird method). Otherwise, the fixed-effects model (Mantel-Haenszel method) was chosen. In this analysis the random-effect mode was used to calculate the pooled SMD with forest plots. Finally 6 studies were pooled for this analysis, including 4 studies from the GEO database and 2 studies from TCGA database. The SMD with 95% CI of miR-146a-5p expression in each group was calculated and pooled.

Results
=======

### Targeted associations of miR-146a-5p and TCSF

miRanda ([Fig. 1A](#f1-or-41-04-2226){ref-type="fig"}) and TargetScanHuman ([Fig. 1B](#f1-or-41-04-2226){ref-type="fig"}) databases revealed that TCSF and miR-146a-5p had target binding sites, while the miRDB database did not have any associated information. As shown in TargetScanHuman ([Fig. 1C](#f1-or-41-04-2226){ref-type="fig"}), an exact match of TCSF and miR-146a-5p to positions 2--8 of the mature miRNA (the seed sequence) followed by an 'A' was defined as an 8mer site.

In total, 47,131 potential target genes were predicted from the database and only 325 target genes, which were repeatedly predicted in 8 or more prediction programs, were chosen for further study. Further GO term enrichment, which included BP, CC and MF, was used to investigate gene function and the biological pathways of target genes. GO and KEGG analyses were performed using the DAVID online tool. The top 10 of KEGG pathways are shown in [Table I](#tI-or-41-04-2226){ref-type="table"}. Additionally, the top 10 BP, CC and MF terms are listed in [Table II](#tII-or-41-04-2226){ref-type="table"}.

A luciferase reporter assay revealed that the fluorescence intensity of the TCSF-wt group was significantly decreased when compared with the TCSF-mut group (P\<0.05; [Fig. 1D](#f1-or-41-04-2226){ref-type="fig"}), which provided strong evidence for the bioinformatics prediction and revealed that miR-146a-5p and TCSF did have binding sites.

### Expression levels of miR-146a-5p and TCSF in TCGA

From the miRNA file of TCGA dataset, many of the 478 tumor tissues and 45 normal lung tissues were involved in LUSC and many of the 521 tumor tissues and 46 normal lung tissues were involved in LUAD. The detection of miRNAs in TCGA targeted the miRNA precursor (pre-miRNA), thus the present study determined the expression of the pre-miRNA has-mir-146a for the mature strand miR-146a-5p. The expression level of miR-146a-5p in LUSC patient tissues was significantly lower when compared with non-cancerous lung tissue (P\<0.0001), while the expression level in LUAD was not statistically significant between the cancerous tissue and non-cancerous lung tissue ([Fig. 2](#f2-or-41-04-2226){ref-type="fig"}). From the transcriptome profiling of the TCGA dataset, many of the 501 tumor tissues and 51 normal lung tissues were involved in LUSC, and many of the 514 tumor tissues and 59 normal lung tissues were involved in LUAD. The expression levels of TCSF in LUSC and LUAD revealed that TCSF was markedly upregulated in cancerous tissues when compared with normal lung tissues (P\<0.05; [Fig. 3](#f3-or-41-04-2226){ref-type="fig"}).

Pearson\'s correlation analysis was conducted to detect the association between miR-146a-5p and TCSF in LUSC and LUAD. It was concluded that there was a negative correlation between the two in LUSC and LUAD (both Pearson r\<0; [Figs. 4](#f4-or-41-04-2226){ref-type="fig"} and [5](#f5-or-41-04-2226){ref-type="fig"}). However, there was no significant difference and further investigation with more tissue samples is required.

The mature miR-146a-5p expressions in the GEO series, together with data in TCGA, were extracted to perform a meta-analysis of the continuous variable SMDs. Four series of data from GEO and the mature miR-146a-5p expression in LUSC and LUAD from TCGA were inputted in Stata software to generate a forest plot ([Fig. 6](#f6-or-41-04-2226){ref-type="fig"}). It can be concluded that miR-146a-5p has the tendency to be downregulated in lung cancer but with no significance (z=0.48, P=0.626) and heterogeneity (I^2^=78.8%, P\<0.001) More samples of lung cancer tissue should be studied to obtain a credible conclusion.

### Experimental evidence of TCSF at the protein level by IHC

The staining status of the TCSF antibody was evaluated by an IHC assay ([Table III](#tIII-or-41-04-2226){ref-type="table"}) and the images of IHC are presented in [Fig. 7](#f7-or-41-04-2226){ref-type="fig"}. In 371 lung cancer tissues, the number of positive TCSF tissues (52.3%) was higher than the negative tissues (47.7%). In the 30 non-cancerous tissues, the number of negative TCSF tissues (86.7%) was greater than the number of positive tissues (13.3%). A significant difference in TCSF expression was observed between lung cancer and non-cancerous lung tissues (P\<0.001) as determined by a non-parametric rank test, which showed that TCSF protein was upregulated in lung cancer tissues. According to an analysis of TCSF expression and the clinicopathological parameters, a greater TCSF expression was significantly associated with a higher pathological grade (P\<0.001), later tumor-node-metastasis stage (P\<0.001), distant metastasis (P=0.003), lymphatic metastasis (P\<0.001) and larger tumor size (P=0.023).

### Effects of TCSF and miR-146a-5p interactions on viability, proliferation and apoptosis in A549 cells

The present study also conducted an in-depth investigation into the biological behavior of A549 cells with TCSF and miR-146a-5p. The influence on cell viability was determined with the CellTiter-Blue Cell Viability Assay kit, as well as a Hoechst 33342 and PI assay. The assay methods all demonstrated that when compared with the scrambled siRNA control group, the cell viability of the group that was transfected with TCSF siRNA was significantly weakened on day 5 and day 10 (P\<0.05). When TCSF siRNA and the miR-146a-5p inhibitor were simultaneously transfected into A549 cells, the cell viability was not significantly different when compared with the siRNA control group. Furthermore, significant differences in cell viability were obtained between the TCSF siRNA and miR-146a-5p mimic group and the scrambled siRNA control group at the two of the monitored time points (P\<0.05; [Fig. 8A and B](#f8-or-41-04-2226){ref-type="fig"}). The proliferation assay using the MTS kit demonstrated a similar trend. Compared with the scrambled siRNA control group, the group that was transfected with TCSF siRNA only and the TCSF siRNA and miR-146a-5p mimic combined transfection group exhibited significantly increased cell proliferation on days 5 and 10 (P\<0.05; [Fig. 8C](#f8-or-41-04-2226){ref-type="fig"}). For the combined TCSF siRNA and miR-146a-5p inhibitor transfection group, the cell proliferation was not significantly different when compared with the scrambled siRNA control group ([Fig. 8C](#f8-or-41-04-2226){ref-type="fig"}) The cell apoptosis assay with the Caspase-3/7 kits revealed that the cell apoptosis of the TCSF siRNA only, TCSF siRNA and miR-146a-5p mimic, and the TCSF siRNA and the miR-146a-5p inhibitor transfection groups were all increased when compared with the control group on day 10 (P\<0.05), but there was no difference on day 5 ([Fig. 8D](#f8-or-41-04-2226){ref-type="fig"}). As for the Hoechst 33342 and PI apoptosis assay, a significant increase was observed in the TCSF siRNA only, TCSF siRNA and miR-146a-5p mimic, and the TCSF siRNA and the miR-146a-5p inhibitor transfection groups on day 5 (P\<0.05), but not on day 10, when compared with the scrambled siRNA control group ([Fig. 8E](#f8-or-41-04-2226){ref-type="fig"}). Thus, the results suggested that there was no effect of adding miR-146a-5p inhibitor or mimic on cell apoptosis. Knockout using TCSF siRNA at different time points revealed that the expression levels of TCSF were significantly lower when compared with the scrambled control group on days 5 and 10 ([Fig. 8F](#f8-or-41-04-2226){ref-type="fig"}). The apoptosis of A549 cells detected by Hoechst 33324 and PI double fluorescent staining under a fluorescent microscope also indicated a similar conclusion to the previous results obtained in the present study (magnification, ×200; [Fig. 9](#f9-or-41-04-2226){ref-type="fig"}).

Discussion
==========

In conclusion, the present study verified the target action association of TCSF and miR-146a-5p via high throughput data analysis and experimental findings for NSCLC. From the binding sites determined through online prediction it was concluded that TCSF may be one of the targeted genes of miR-146a-5p. The results of a dual-luciferase assay with statistically significant results provided evidence to support this conclusion. In addition, miR-146a-5p and TCSF had opposite effects on cell viability, proliferation and apoptosis, which revealed that they may have roles in NSCLC development.

To the best of our knowledge, miRNA negatively regulates targeted mRNA by following two main mechanisms. One is through complementary base sequences of miRNA and mRNA. Through this approach, the binding domain is always located in the coding region or Open Reading Frame of mRNA and leads to full degradation of mRNA, which requires a small portion of the miRNA regulatory mechanism ([@b50-or-41-04-2226]--[@b52-or-41-04-2226]). The other approach is incomplete complementation of miRNA and mRNA sequences. The binding area is often located in the 3′-untranslated region (non-coding region) of mRNA. These circumstances can lead to the suppression of the protein translational level or influence targeted mRNA stability. This regulatory approach occurs in the majority of mammals. A single miRNA has multiple targeted mRNAs, and one mRNA could also be regulated by multiple miRNAs in reverse ([@b21-or-41-04-2226],[@b22-or-41-04-2226],[@b50-or-41-04-2226]--[@b52-or-41-04-2226]).

In our previous study, 3 targeted genes of miR-146a were researched and reported: EGFR ([@b20-or-41-04-2226]), interleukin-1 receptor-associated kinase 1 (IRAK1) ([@b53-or-41-04-2226]) and tumor necrosis factor receptor-associated factor 6 (TRAF6) ([@b54-or-41-04-2226]). Inducing miR-146a could enhance the proliferation capacity of NSCLC cells via drugs that targeted the EGFR ([@b20-or-41-04-2226]). IRAK1 and TRAF6 were confirmed to have an association with the progression of NSCLC ([@b53-or-41-04-2226],[@b54-or-41-04-2226]). In addition, their effects on miR-146a-5p in NSCLC have been validated by our group. Furthermore, more targeted genes of miR-146a-5p were studied and the miRTarBase ([mirtarbase.mbc.nctu.edu.tw/php/index.php](mirtarbase.mbc.nctu.edu.tw/php/index.php)) database was used to collect the experimentally validated miRNA-target interactions in various cancers ([@b55-or-41-04-2226]). In the miRTarBase database, until now, only 70 targeted genes of hsa-miR-146a-5p have been listed with results from a reporter assay, western blotting, qPCR, microarray, next-generation sequencing technology, amino acids in cell culture or through other methods. Among these genes, the present study consulted the literature to confirm the results of miRTarBase. For example, miR-146a has a critical role in the apoptosis of androgen-independent prostate cancer cells in which it targets Rho associated coiled-coil containing protein kinase 1 (ROCK1) through regulation of the ROCK/Caspase 3 signaling pathway ([@b56-or-41-04-2226]). VEGFA, EGFR2, phosphatase and tensin homolog, and C-X-C chemokine receptor type 4 may serve a significant role in the pathogenesis of endometriosis by being a target for miR-146a-5p and other miRNAs ([@b57-or-41-04-2226]). The Fanconi Anemia/BRCA pathway in chronic myeloid leukemia involves the target genes ATR serine/threonine kinase (ATR) and the ATR interacting protein of miR-146a-5p ([@b58-or-41-04-2226]). The present study verified a novel target gene of miR-146a-5p, which was TCSF.

Bioinformatic prediction serves an increasingly significant role in the research into miRNA, and prediction databases have become more and more capable of performing accurate predictions. The predictions mainly include machine algorithms and experimental validation. The miRNA miRanda database, the first miRNA targeted gene prediction database established in 2003, can list the targeted mRNAs of miRNAs and show the binding sites by selecting alignment details with an algorithm similar to Smith-Waterman ([@b29-or-41-04-2226]). The miRDB database can also predict the targeted genes of miRNAs and the possible miRNAs that bind to mRNA genes ([@b30-or-41-04-2226]). From the TargetScanHuman database one can download the predicted mRNAs of miRNAs similar to the other two databases ([@b32-or-41-04-2226],[@b33-or-41-04-2226]). Due to the different predicted algorithms applied to different databases, the targeted genes and quantity outcomes are different from each other. Taking the intersection of the genes from different databases could enhance the credibility of the prediction.

The present study predicted the targeted genes *in silico* and combined the reports from previous studies, then selected TCSF as one of the targets of miR-146a-5p. Following further investigation, a dual luciferase reporter assay system provided evidence supporting the association between TCSF and miR-146a-5p. As is reported by Zhang *et al* ([@b59-or-41-04-2226]), in hepatocellular carcinoma (HCC) miR-146a inhibited the invasion and metastasis of HCC cells by targeting HAb18G to downregulate NF-κB p65 and repress VEGF expression via the upregulation of adenomatosis polyposis coli tumor suppressor through multiple pathways. Furthermore, the present study investigated the function of TCSF and miR-146a-5p in NSCLC cells at the mRNA and protein expression levels *in vitro*. When the miR-146a-5p inhibitor and TCSF siRNA were transfected into the cells concurrently, the influence of cell viability and proliferation was weaker than that observed when cells were transfected with TCSF siRNA only. Additionally, when the miR-146a-5p mimic and TCSF siRNA were transfected in combination, the effect on cell viability and proliferation was stronger than the single treatment with TCSF siRNA. However, in the apoptosis experiments, TCSF siRNA could markedly enhance cell apoptosis on day 10, while no effect was observed following transfection with miR-146a-5p inhibitor or mimic. All of these phenotypes demonstrated that miR-146a-5p could weaken the viability and proliferation effects of TCSF in the NSCLC cells. When miR-146a-5p was removed, TCSF had a stronger impact on NSCLC cells. Since the present study transfected TCSF siRNA only as a comparison, NSCLC cell viability and proliferation were downregulated. It could be concluded that TCSF promoted NSCLC cell growth and repressed its demise. Conversely, the downregulation of miR-146a-5p negatively could regulate the upregulation of TCSF in NSCLC. However, the associated regulatory mechanism underlying this signaling pathway requires further study. As a result, they worked in NSCLC together to regulate tumor infiltration, invasion, metastasis and apoptosis.

In conclusion, the present study verified the association between TCSF and miR-146a-5p, and explored their roles in NSCLC cells. However, further research is required to investigate the signaling pathway through which miR-146a-5p targets TCSF in NSCLC. Therefore, TCSF may be a novel clinical therapeutic target for NSCLC in the future.
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![Targeted association between miR-146a-5p and TCSF. (A) The binding sites of miR-146a-5p and TCSF in miRanda. (B) The binding sites of miR-146a-5p and TCSF in TargetScanHuman. (C) miR-146a-5p and TCSF binding involves 8mer sites according to TargetScanHuman. (D) A dual luciferase reporter assay system revealed that miR-146a-5p and TCSF did have complementary sequences. \*P\<0.05 vs. TCSF-mut. miR/miRNA, microRNA; TCSF, tumor collagenase stimulatory factor; wt, wild-type; mut, mutant; ORF, open reading frame.](OR-41-04-2226-g00){#f1-or-41-04-2226}

![Expression of mir-146a in NSCLC from The Cancer Genome Atlas. (A) LUSC: n=478 cancerous tissues and n=45 normal non-cancerous tissues. (B) LUAD: n=521 cancerous tissues and n=46 normal non-cancerous tissues. miR, microRNA; TCSF, tumor collagenase stimulatory factor; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma.](OR-41-04-2226-g01){#f2-or-41-04-2226}

![Expression of TCSF in LUSC and LUAD from The Cancer Genome Atlas database. (A) LUSC: n=501 cancerous tissues and n=51 normal non-cancerous tissues. (B) LUAD: n=514 cancerous tissues and n=59 normal non-cancerous tissues. TCSF, tumor collagenase stimulatory factor; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma.](OR-41-04-2226-g02){#f3-or-41-04-2226}

![Negative correlation between mir-146a and TCSF expression in LUSC from TCGA database. (A) Correlation curve and (B) expression of mir-146a and TCSF. miR, microRNA; TCSF, tumor collagenase stimulatory factor; LUSC, lung squamous cell carcinoma; TCGA, The Cancer Genome Atlas.](OR-41-04-2226-g03){#f4-or-41-04-2226}

![Negative correlation between mir-146a and TCSF expression in LUAD from TCGA database. (A) Correlation curve and (B) expression of mir-146a and TCSF. miR, microRNA; TCSF, tumor collagenase stimulatory factor; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.](OR-41-04-2226-g04){#f5-or-41-04-2226}

![Forest plot of microRNA-146a-5p expression levels in patients with lung cancer from the Gene Expression Omnibus and TCGA databases. SMD, Standard mean difference; CI, confidence intervals; TCGA, The Cancer Genome Atlas; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma.](OR-41-04-2226-g05){#f6-or-41-04-2226}

![H&E and IHC staining of tumor collagenase stimulatory factor expression in non-small cell lung cancer. (A) H&E staining of LUAD (magnification, ×100). (B) IHC of LUAD (magnification, ×100). (C) H&E staining of LUSC (magnification, ×100). (D) IHC of LUSC (magnification, ×100). H&E, hematoxylin and eosin; IHC, immunohistochemistry; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](OR-41-04-2226-g06){#f7-or-41-04-2226}

![Detection of the effects of miR-146a-5p and TCSF on lung cancer A549 cell viability, proliferation and apoptosis. Cell viability was determined by (A) CellTiter-Blue and (B) Hoechst 33342. (C) Cell proliferation was analyzed using an MTS kit. Cell apoptosis was assessed via (D) Caspaes3/7 assays and (E) Hoechst 33342. (F) The knockout effect of TCSF siRNA at different time points. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. scrambled siRNA. miR, microRNA; TCSF, tumor collagenase stimulatory factor; siRNA, small interfering RNA.](OR-41-04-2226-g07){#f8-or-41-04-2226}

![Apoptosis of lung cancer A549 cells was detected by Hoechst 33342 and propidium iodide double fluorescent staining under a fluorescent microscope (magnification, ×200). miR, microRNA; TCSF, tumor collagenase stimulatory factor; siRNA, small interfering RNA.](OR-41-04-2226-g08){#f9-or-41-04-2226}

###### 

Kyoto Encyclopedia of Genes and Genomes pathway analysis of miR-146-5p target genes.

  Term                                  Count   \%         P-value        Genes
  ------------------------------------- ------- ---------- -------------- --------------------------------------------------------------------
  hsa04724:Glutamatergic synapse        9       2.893891   6.200×10^−4^   PRKCA, SLC1A2, ADCY2, ADCY9, PPP3R2, GRIA3, PRKACB, GRIN3A, SLC1A1
  hsa04918:Thyroid hormone synthesis    7       2.250804   1.075×10^−3^   PRKCA, ADCY2, GPX6, ADCY9, CREB3L1, PRKACB, LRP2
  hsa04530:Tight junction               9       2.893891   2.047×10^−3^   PPP2R1B, PRKCA, NRAS, RAB3B, MAGI3, PRKCI, PARD6G, PRKCE, YES1
  hsa04310:Wnt signaling pathway        9       2.893891   2.143×10^−3^   PRKCA, PRICKLE2, RAC1, SMAD4, PPP3R2, FZD3, PRKACB, NFATC2, DAAM2
  hsa04727:GABAergic synapse            7       2.250804   2.926×10^−3^   PRKCA, GABRG1, GAD2, ADCY2, TRAK2, ADCY9, PRKACB
  hsa04370:VEGF signaling pathway       6       1.92926    3.441×10^−3^   PRKCA, NRAS, PTGS2, RAC1, PPP3R2, NFATC2
  hsa04390:Hippo signaling pathway      9       2.893891   3.745×10^−3^   PPP2R1B, BMPR2, SMAD4, PRKCI, YWHAB, TEAD1, FZD3, PARD6G, YAP1
  hsa04152:AMPK signaling pathway       8       2.572347   4.285×10^−3^   PPP2R1B, IRS2, CAB39L, SLC2A4, SCD, ELAVL1, CREB3L1, PRKAA2
  hsa05031:Amphetamine addiction        6       1.92926    4.838×10^−3^   PRKCA, PPP3R2, CREB3L1, GRIA3, PRKACB, GRIN3A
  hsa04921:Oxytocin signaling pathway   9       2.893891   4.926×10^−3^   PRKCA, NRAS, ADCY2, ADCY9, PTGS2, PPP3R2, PRKACB, PRKAA2, NFATC2

###### 

Gene Ontology term enrichment analysis for the most significantly associated targets of miR-146-5p.

  Category           Term                                                                                                                        Count   \%         P-value        Genes
  ------------------ --------------------------------------------------------------------------------------------------------------------------- ------- ---------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GOTERM_BP_DIRECT   GO:0006511\~ubiquitin-dependent protein catabolic process                                                                     10    3.215434   3.368×10^−3^   USP30, PSMF1, USP6, USP3, UBE2G1, SIAH2, ITCH, USP33, ZNRF3, USP31
  GOTERM_BP_DIRECT   GO:0042759\~long-chain fatty acid biosynthetic process                                                                          3   0.96463    3.920×10^−3^   MYO5A, SCD, QKI
  GOTERM_BP_DIRECT   GO:0060071\~Wnt signaling pathway, planar cell polarity pathway                                                                 7   2.250804   4.238×10^−3^   PSMF1, PRICKLE2, RAC1, ROR1, FZD3, ZNRF3, PSMB11
  GOTERM_BP_DIRECT   GO:0007411\~axon guidance                                                                                                       9   2.893891   5.041×10^−3^   NRP2, NRAS, KLF7, TNR, PTPRA, RAC1, SMAD4, SIAH2, USP33
  GOTERM_BP_DIRECT   GO:0061549\~sympathetic ganglion development                                                                                    3   0.96463    9.105×10^−3^   NRP2, PHOX2B, FZD3
  GOTERM_BP_DIRECT   GO:0035329\~hippo signaling                                                                                                     4   1.286174   9.788×10^−3^   YWHAB, TEAD1, YAP1, AMOTL2
  GOTERM_BP_DIRECT   GO:0014047\~glutamate secretion                                                                                                 4   1.286174   1.083×10^−2^   SYT1, SLC1A2, PPFIA1, SLC1A1
  GOTERM_BP_DIRECT   GO:0046326\~positive regulation of glucose import                                                                               4   1.286174   1.310×10^−2^   SLC1A2, IRS2, PRKCI, CREBL2
  GOTERM_BP_DIRECT   GO:0003091\~renal water homeostasis                                                                                             4   1.286174   1.562×10^−2^   ADCY2, ADCY9, PRKACB, AQP1
  GOTERM_BP_DIRECT   GO:0010634\~positive regulation of epithelial cell migration                                                                    4   1.286174   1.698×10^−2^   DOCK1, BMPR2, CLASP2, PRKCE
  GOTERM_MF_DIRECT   GO:0005515\~protein binding                                                                                                 177     56.91318   5.430×10^−4^   DLC1, SYT1, PTGS2, XPO5, INTS2, JAG1, SPRTN, GRIN3A, AQP1, AMOTL2, ZNRF3, ERLEC1, IQGAP1, TRAK2, SLC2A4, FBXO28, MAP3K8, MS4A1, CREB3L1, ITCH, etc.
  GOTERM_MF_DIRECT   GO:0001077\~transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding     13    4.180064   7.000×10^−4^   PHOX2B, KLF13, GABPA, ONECUT2, SMAD4, TEAD1, SIX4, MYBL1, ZIC1, TCF21, CREB3L1, POU3F2, NFATC2
  GOTERM_MF_DIRECT   GO:0000978\~RNA polymerase II core promoter proximal region sequence-specific DNA binding                                     14    4.501608   7.493×10^−3^   PHOX2B, KLF13, MTA2, GABPA, ONECUT2, SMAD4, TEAD1, SIX4, MYBL1, ZIC1, GCFC2, ZNF148, POU3F2, NFATC2
  GOTERM_MF_DIRECT   GO:0003700\~transcription factor activity, sequence-specific DNA binding                                                      27    8.681672   1.215×10^−2^   ZNF641, KLF7, ELF2, ZNF532, TFCP2L1, MTA2, ZFX, GABPA, SMAD4, TEAD1, ZNF367, NFIX, PARK2, ZIC1, MYT1, GCFC2, TCF20, HSF5, CREB3L1, ZSCAN25, ZNF540, POU3F2, NFATC2, ZNF605, ZNF449, CREBL2, KLF3
  GOTERM_MF_DIRECT   GO:0004697\~protein kinase C activity                                                                                           3   0.96463    2.580×10^−2^   PRKCA, PRKCI, PRKCE
  GOTERM_MF_DIRECT   GO:0004970\~ionotropic glutamate receptor activity                                                                              3   0.96463    2.580×10^−2^   GRIA3, GRIN3A, GRID1
  GOTERM_MF_DIRECT   GO:0015501\~glutamate:sodium symporter activity                                                                                 2   0.643087   3.348×10^−2^   SLC1A2, SLC1A1
  GOTERM_MF_DIRECT   GO:0005234\~extracellular-glutamate-gated ion channel activity                                                                  3   0.96463    3.637×10^−2^   GRIA3, GRIN3A, GRID1
  GOTERM_MF_DIRECT   GO:0061630\~ubiquitin protein ligase activity                                                                                   8   2.572347   3.980×10^−2^   TRIM37, XIAP, UBE2G1, UBR1, SIAH2, PARK2, ITCH, ZNRF3
  GOTERM_MF_DIRECT   GO:0003723\~RNA binding                                                                                                       16    5.144695   4.576×10^−2^   XPO5, SRSF12, SYNJ1, KIAA0430, ELAVL1, DIS3L, EARS2, LARP6, EIF4G2, TRMT1L, SRSF6, DCP2, QKI, CELF2, SYNJ2, STRBP
  GOTERM_CC_DIRECT   GO:0005737\~cytoplasm                                                                                                       114     36.65595   2.000×10^−4^   DLC1, ADCY2, PTGS2, XPO5, AQP1, ZIC1, IQGAP1, TRAK2, MAP3K8, ITCH, ZNF641, SIX4, UBR1, DIS3L, MARK1, EARS2, ST13, TRIM37, CCDC6, PDGFRA, etc.
  GOTERM_CC_DIRECT   GO:0030424\~axon                                                                                                              13    4.180064   2.790×10^−4^   NRP2, CCK, KCNC3, HTT, FZD3, IQGAP1, FAM168B, EIF4G2, GAD2, ADCY9, SYNJ2, OLFM1, DTNA
  GOTERM_CC_DIRECT   GO:0005829\~cytosol                                                                                                           77    24.75884   7.070×10^−4^   DLC1, PHKB, XPO5, SYNJ1, IQGAP3, TTPA, FERMT1, WWC2, AMOTL2, IQGAP1, PRMT3, TRIM5, SLC2A4, TRIM8, MAP3K8, SYNJ2, YAP1, ITCH, PRKACB, PRKCA, etc.
  GOTERM_CC_DIRECT   GO:0043005\~neuron projection                                                                                                 11    3.536977   5.420×10^−3^   MYO5A, SYT1, SYNPR, PTGS2, ARHGEF7, SYNJ1, LIN7C, SIAH2, GRIN3A, PARK2, IQGAP1
  GOTERM_CC_DIRECT   GO:0005776\~autophagosome                                                                                                       5   1.607717   2.001×10^−2^   C9ORF72, HTT, USP33, ZFYVE1, PIP4K2B
  GOTERM_CC_DIRECT   GO:0016324\~apical plasma membrane                                                                                            11    3.536977   2.058×10^−2^   MTDH, BMPR2, PRKCI, STC1, FZD3, JAG1, LRP2, AQP1, AMOTL2, SLC1A1, SLC46A1
  GOTERM_CC_DIRECT   GO:0005884\~actin filament                                                                                                      5   1.607717   2.105×10^−2^   MYO5A, ACTC1, RAC1, YES1, IQGAP1
  GOTERM_CC_DIRECT   GO:0080008\~Cul4-RING E3 ubiquitin ligase complex                                                                               3   0.96463    3.026×10^−2^   DCAF5, DCAF12, DCAF17
  GOTERM_CC_DIRECT   GO:0005654\~nucleoplasm                                                                                                       58    18.64952   3.395×10^−2^   C9ORF72, ELF2, ZBTB34, CDC14A, XPO5, FAM20B, YLPM1, INTS2, SPRTN, ZIC1, TRIM8, ZNF148, ZNF540, YAP1, PRKACB, PRKCA, ZNF641, MTA2, GABPA, TIMELESS, etc.
  GOTERM_CC_DIRECT   GO:0043234\~protein complex                                                                                                   13    4.180064   3.658×10^−2^   NOS1, PTGS2, HTT, ARHGEF7, MTA2, YWHAB, PRKCI, PARK2, IQGAP1, ST13, PDGFRA, PARD6G, DTNA

GO, Gene Ontology.

###### 

Association between tumor collagenase stimulatory factor expression and clinicopathological parameters by immunohistochemistry.

  Clinicopathological parameter                                       Total number   TCSF (−), n (%)   TCSF (+), n (%)   Z score   P-value
  ------------------------------------------------------------------- -------------- ----------------- ----------------- --------- ---------------------------------------------------------
  Tissue                                                                                                                 −4.1      P\<0.001^[d](#tfn5-or-41-04-2226){ref-type="table-fn"}^
    Cancerous                                                         371            177 (47.7)        194 (52.3)                  
    Non-cancerous                                                       30           26 (86.7)         4 (13.3)                    
  Pathological type                                                                                                      2.393     0.122
    Lung adenocarcinoma                                               127            64 (50.4)         63 (49.6)                   
    Lung squamous cell carcinoma                                      175            88 (50.3)         87 (49.7)                   
    Lung adenosquamous carcinoma                                        28           11 (39.3)         17 (60.7)                   
    Undifferentiated carcinoma                                            8          3 (37.5)          5 (62.5)                    
    Small cell lung cancer                                              26           10 (38.5)         16 (61.5)                   
    Large cell lung cancer                                                1          1 (100)           0 (0)                       
    Other lung cancer                                                     6          0 (0)             6 (100)                     
  Sex                                                                                                                    −1.017    0.309
    Male                                                              299            158 (52.8)        141 (47.2)                  
    Female                                                              96           45 (46.9)         51 (53.1)                   
  Age, years                                                                                                             −0.416    0.678
    ≤60                                                               218            114 (52.3)        104 (47.7)                  
    \>60                                                              177            89 (50.3)         88 (49.7)                   
  Pathological grade^[a](#tfn2-or-41-04-2226){ref-type="table-fn"}^                                                      19.065    P\<0.001^[d](#tfn5-or-41-04-2226){ref-type="table-fn"}^
    I                                                                   39           27 (69.2)         12 (30.8)                   
    II                                                                  92           53 (57.6)         39 (42.4)                   
    III                                                               131            46 (35.1)         85 (64.9)                   
  TNM stage                                                                                                              −3.775    P\<0.001^[d](#tfn5-or-41-04-2226){ref-type="table-fn"}^
    I--II                                                             299            159 (53.2)        140 (46.8)                  
    III--IV                                                             63           17 (27.0)         46 (73.0)                   
  Distant metastasis                                                                                                     −2.953    0.003^[c](#tfn4-or-41-04-2226){ref-type="table-fn"}^
    No                                                                346            174 (50.3)        172 (49.7)                  
    Yes                                                                 16           2 (12.5)          14 (87.5)                   
  Lymphatic metastasis                                                                                                   −7.519    P\<0.001^[d](#tfn5-or-41-04-2226){ref-type="table-fn"}^
    No                                                                234            148 (63.2)        86 (36.8)                   
    Yes                                                               128            28 (21.9)         100 (78.1)                  
  Tumor size, cm                                                                                                         −2.272    0.023^[b](#tfn3-or-41-04-2226){ref-type="table-fn"}^
    ≤7                                                                314            160 (51.0)        154 (49.0)                  
    \>7                                                                 48           16 (33.3)         32 (66.7)                   

Pathological grade group pairwise comparison: Pathology grade I vs. Pathology grade III (Pearson Chi-Square=14.276, P\<0.001) and Pathology grade II vs. Pathology grade III (Pearson Chi-Square=11.078, P=0.001) were significantly different. Pathology grade I vs. Pathology grade II (Pearson Chi-Square=1.556, P=0.244) was not significantly different.

P\<0.05

P\<0.01

P\<0.001. TNM, tumor-node-metastasis; TCSF, tumor collagenase stimulatory factor.
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